Recent advances demonstrated the key roles that the dysregulated mRNA translation and degradation machinery play in various diseases, including cancers. This is further evidenced by development of numerous drugs that target these mechanisms and are in various stages of clinical trials or in clinical use. We study the cellular mechanisms that control mRNA translation and degradation and their roles in patho-phyisiologal contexts such as anti-viral immune response and cancer cells’ response to treatments.